THE BOTTOM LINE
The October 28 policy covers BPC-157 acetate as a subcutaneous, intramuscular, oral or topical product. Injectables must use an FDA 510(k)-cleared syringe. Oral products need documentation that the formula is adequately absorbed, which is an open question for a peptide taken by mouth. Which form fits you is a clinician's call, not a marketing page's.
SIDE-BY-SIDE
What actually differs
Why the absorption condition matters
Peptides are often broken down in the gut, so an oral product has to show it delivers the drug. The policy puts that burden on the compounder. Ask the provider what absorption documentation the pharmacy relies on. A vague answer tells you something.
Questions for the clinician
Why this route for my goal? What dose, for how long, and what happens at the end? What side effects should make me stop and call? How do I report a serious reaction? A clinician who answers these is doing the job the policy assumes they're doing.
QUICK ANSWERS
Is oral BPC-157 covered by the HHS policy?
Yes, oral BPC-157 acetate is a listed route, but the compounder needs documentation that the formula is adequately absorbed.
PRIMARY & AUTHORITATIVE SOURCES
Check the underlying record
Regulatory status and labeling can change. Sources were reviewed on the article update date; current prescribing information controls.PROVIDER TO CHECK
Live Vital
A physician-supervised telehealth company offering compounded BPC-157 under the October 28 policy, with treatment decisions made by a licensed clinician. Run it through the seven questions on our BPC-157 review before you start.
Check BPC-157 eligibility at Live Vital →Televetted may earn a commission if you sign up through this link. Payment never changes the facts we report. This is not a rating under the Televetted Method.COMPARE THE CARE MODEL
Medication is only one part of the decision.
Use the 30-second filter to identify the costs, clinical safeguards and service terms worth checking before you enroll.
Find my starting point →